-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
Today (June 1) Baoyuan Pharmaceutical and Cinda Bio announced that the two parties have reached an agreement to authorize Cinda Bio as an exclusive partner to jointly develop and commercialize in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).
As a next-generation tyrosine kinase inhibitor (TKI) under development that targets ROS1 and NTRK, taletrectinib is effective for patients with ROS1-positive non-small cell lung cancer that have not been treated with TKI and have been treated with TKI.
At present, treatment drugs for patients with ROS1-positive lung cancer and NTRK-positive solid tumors are still limited, and most patients will develop drug resistance after a period of treatment with existing drugs.
As of January 15, 2021, an ongoing phase 2 clinical trial of taletrectinib (TRUST) showed that among 11 patients with advanced ROS1-positive non-small cell lung cancer who have not been treated with ROS1 TKI, the investigator’s objective remission rate ( ORR) is 100%; at the same time taletrectinib shows good safety.
According to the terms of the agreement, Cinda Bio will obtain the joint development and commercialization rights of taletrectinib in the Greater China region with Baoyuan Pharmaceutical as an exclusive partner.
Note: The original text has been deleted
